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About a decade ago a multiple myeloma patient 
demonstrated a complete response to a proteasome 
inhibitor Bortezomib. This case generated a lot of 
hopes, and after successful clinical trials Bortezomib 
was approved by FDA and became the drug of choice 
for this disease. A high sensitivity of multiple myeloma 
to proteasome inhibition is probably related to extensive 
production immunoglobulins by the cancer cells. 
Bortezomib prevents degradation of these proteins, which 
accumulate and cause a strong ER stress, eventually 
triggering apoptosis [1, 2]. Unfortunately, many patients 
show only partial response to Bortezomib, in part due 
to the development of resistance [3]. Among multiple 
mechanism of resistance to Bortezomib, cells upregulate 
expression of molecular chaperones, e.g. Hsp27, which 
protect from the buildup of abnormal protein species [4-
7]. The balance between toxicity of abnormal polypeptides 
and  protective  function  of  chaperones  defines  the 
outcome of the treatment with proteasome inhibitors. 
Bortezomib has also been tested in trials for 
treatment of solid tumors, either alone or in combination 
with other drugs, and results have been promising. The 
selective sensitivity of various cancer cells to proteasome 
inhibitors as compared to normal cells is probably because 
cancer cells have to handle higher levels of abnormal 
polypeptides, since they are exposed to adverse conditions 
of tumor microenvironments, oxidative stress and because 
of genetic instability and associated accumulation of 
mutant proteins [8]. Accordingly, cancer cells often have 
increased levels of molecular chaperones, like Hsp72 or 
Hsp27, as well as the heat shock transcription factor Hsf1 
[9]. Furthermore, it was found that cancers have special 
requirements for these factors, since Hsf1 and hsp72 
knockout mice demonstrate dramatic resistance to certain 
types of cancer, e.g. skin or breast cancer [10-12]. These 
data led to a concept of the “non-oncogene addiction” 
of cancers to Hsf1 and molecular chaperones, and 
predicted that inhibition of chaperones could be a potent 
novel approach towards development of therapeutics 
[8]. In fact, there have been number of publications that 
pharmacological inhibition or siRNA-mediated depletion 
of Hsf1, Hsp72 or Hsp27 can selectively cause apoptosis 
or growth inhibition in various types of cancer [9, 13]. 
Furthermore, anti-sense RNA against Hsp27 has been 
tested and demonstrated promising results with bladder 
cancer [14, 15]. Since downregulation of Hsf1 or 
chaperones increases the generation of abnormal proteins, 
while inhibition of proteasome blocks their degradation, 
the combination of these treatments could synergistically 
precipitate a selective demise of cancer cells. Indeed, it 
was demonstrated that downregulation or inhibition of 
Hsf1 can potently enhance sensitivity of cancer cells 
to Bortezomib [16, 17]. Accordingly, a lot of efforts 
and resources have been invested in academic labs and 
industry in development of inhibitors of Hsf1 and various 
chaperones, but so far there have been no breakthroughs.
The paper by Neznanov et al. [18] offers an 
alternative approach towards sensitization of cancer 
cells to proteasome inhibitors. Instead of inhibition of 
chaperones, this group proposes to cause a buildup of 
abnormal polypeptides by heat shock. They demonstrated 
that a mild non-toxic heat shock strongly enhances 
apoptosis caused by sub-toxic concentrations of 
Bortezomib. Although there are no data on the effects 
of heat shock beyond cell culture models, an interesting 
possibility is that a combination of local hyperthermia and 
Bortezomib could be beneficial for treatment of localized 
tumors. Furthermore, since only mild heat treatment was 
necessary for the synergistic effect with Bortezomib, 
there is a possibility that the fever-range temperature, 
which could be triggered by pyrogenes can be sufficient 
for enhancement of Bortezomib-induced anti-cancer 
effects. This possibility opens up a range of approaches 
towards treatment. 
As an alternative way of generating abnormal 
proteins, the authors used puromycin. This inhibitor 
accepts growing polypeptide chains, and aborts further 
growth, leading to the release of incomplete chains, 
which of course cannot fold properly and are toxic. At 
low sub-toxic concentrations, puromycin could strongly 
potentiate killing of cancer cells by Bortezomib. In 
this set of experiments, the authors tested not only cell 
culture models, but also a mouse model of multiple 
myeloma. They demonstrated that Bortezomib alone 
only partially reduced growth of multiple myeloma 
tumors transplanted into syngenic animals. On the other 
hand, a combination of Bortezomib and low doses of 
puromycin led to almost complete inhibition. Overall, the 
combination of proteasome inhibitors with puromycin, 
heat shock or other treatments that generate a buildup 
of abnormal polypeptides represents a novel, and 
potentially powerful approach towards cancer treatment. Oncotarget 2011; 2:  356 - 357 357 www.impactjournals.com/oncotarget
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